Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- Status
- TERMINATED
- Phase
- PHASE2
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Status
- COMPLETED
- Phase
- PHASE2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Status
- RECRUITING
- Phase
- PHASE2